Monoclonal Antibody Caninization

Creative Biolabs offers professional monoclonal antibody caninization service. Although human therapeutic antibodies have significantly improved human's capacity of fighting diseases, therapeutic antibodies have not made such achievements in pets and other important agriculture animals. Our novel antibody caninization service enables therapeutic use of antibodies derived from any resources for dog use.

Relying on our unparalleled expertise in antibody engineering and affinity maturation, monoclonal antibodies with a variety of species background, such as human, mouse, rabbit, rat, chicken, bovine, can be successfully caninized without specificity switch and with equal or higher affinity than that of original antibody. Antibody caninization is performed using standard CDR grafting method followed by construction and screening of a caninized phage display antibody library with rationally designed back mutations.

Also, antibody caninization service provides the opportunity to test therapeutic antibodies intended for humans and other species in dog animal models. In comparison with tests in rodents, the tests for the caninized form of an original antibody in dogs will produce more relevant data regarding activity, efficacy and safety of the antibody for clinical use. A clearly defined mechanism of action of the caninized antibody in dogs will significantly facilitate drug development and patent application.

Besides antibody caninization services, we are also the only company that provides antibody murinization service and one of the best companies that provides antibody humanization service.

Other optional antibody engineering services:

• Antibody Affinity Maturation
• Antibody Stability Improvement
• Simianization of Non-monkey Antibodies
• Monoclonal Antibody Murinization Service
• Custom Cysteine Modification in Antibody

Published Data

• Caninized Anti-Canine PD-1 Antibodies

Fig. 2 Tumor response of caninized anti-canine PD-1 antibodies in dogs with target tumor lesions. (Masaya Igase, 2024)

Anti-programmed death 1 (PD-1) antibodies have played a role as traditional Chinese medicine in treating varieties of tumors. Researchers have previously developed caninized anti-canine PD-1 antibodies and evaluated their therapeutic properties in dogs with advanced oral malignant melanoma (OMM) through various trials. Here, they recruited 38 dogs with non-OMM solid tumors and treated the dogs with caninized anti-canine PD-1 antibodies. The results showed that caninized anti-canine PD-1 antibodies were well tolerated in non-OMM dogs, with a few cases showing adverse reactions. These data provide the basis for conducting large-scale clinical trials of anti-PD-1 antibody therapy in dogs.

FAQ

1. What is antibody caninization?

   Antibody caninization is the process of modifying non-canine antibodies, typically human or murine, to resemble canine antibodies more closely. This is done by grafting the antigen-binding regions of the original antibody onto a canine antibody framework. This technique helps reduce immunogenicity and improves the therapeutic efficacy of the antibody when used in canine species.

2. Why is antibody caninization important in veterinary medicine?

   Caninized antibodies are crucial because they are specifically engineered to be less immunogenic and more effective in dogs. This specificity is vital in treating diseases such as cancer, autoimmune disorders, and infectious diseases in dogs with therapies that are tailored to their immune system, thus maximizing the treatment's efficacy and safety.

3. What are the potential applications of caninized antibodies in dogs?

   Caninized antibodies are used in various therapeutic areas including oncology, where they can target specific cancer cells without harming healthy cells. They are also used in the treatment of autoimmune diseases by modulating the immune system's response, and in the management of chronic pain or allergies by blocking specific pathways involved in these conditions.

4. How are caninized antibodies developed?

   The development of caninized antibodies involves several steps, starting with the selection of a target antigen and the original antibody (human or mouse). The complementary determining regions (CDRs) of the original antibody are then genetically engineered into a canine antibody framework. This hybrid antibody is then expressed, purified, and tested in vitro and in vivo to ensure it retains its antigen-binding properties while being less likely to be rejected by the dog's immune system.

5. What are the benefits of using caninized antibodies over fully human or murine antibodies in dogs?

   Caninized antibodies are preferred because they are specifically engineered to interact effectively with the canine immune system, reducing the risk of immune reactions such as allergies or anaphylaxis. This compatibility enhances the therapeutic efficacy and safety profile when treating dogs, as opposed to using fully human or murine antibodies that might be recognized as foreign, leading to immune rejection or reduced effectiveness.

6. Can caninized antibodies be used for diagnostic purposes in dogs?

   Caninized antibodies can be employed in diagnostic applications for detecting specific diseases or conditions in dogs. They are used in various diagnostic tests, including ELISA, immunohistochemistry, and flow cytometry, to accurately identify markers that are indicative of diseases such as cancers or infectious diseases, ensuring that the diagnostic tools are specifically tailored to canine antigens.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.